Club races back to growth as turnover nears HK$140bn
The city's gaming operator says it welcomed more than 1.7 million people to racecourses in the 2024-25 season. Photo: Hong Kong Jockey Club
Betting turnover for races has risen by 3 percent to nearly HK$140 billion over the latest horse racing season that concluded on Wednesday, with the city's gaming operator calling the increase "a very encouraging return to growth".
The Hong Kong Jockey Club, which announced the results on Thursday, also said it welcomed more than 1.7 million people to its racecourses, up more than 13 percent from 2023-24.
Among those turning up at the racecourses were a record 195,700 tourists from the mainland.
"It has been a real pleasure to welcome so many tourists from overseas and the mainland to our racecourses and to see how much they appreciate the unique quality of our racecourse experience, which is truly like no other," said chief executive Winfried Engelbrecht-Bresges.
"Next season there will be even more to impress them, including an entirely new arrival experience at Sha Tin Racecourse."
Racing turnover was more than HK$138.8 billion, representing a 3 percent increase.
"This is a very encouraging return to growth after the 4.5 percent decline last season, and reflects the success of strategies introduced last year," the club said, attributing the rise to factors such as rising mainland and international sports tourism.
The 847 Hong Kong races held across 88 meetings attracted HK$125.7 billion in turnover, while over HK$13.1 billion was wagered in 393 overseas simulcast races.
The betting income from local customers, however, dropped 0.7 percent.
Betting duties for the latest season came in at HK$12.8 billion, down 0.8 percent.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RTHK
2 days ago
- RTHK
DSE candidates face 4pc rise in fees for 2026 exams
DSE candidates face 4pc rise in fees for 2026 exams The HKEAA says fees and charges are going up to optimise use of resources and maintain its long-term stability. File photo: RTHK The exams body on Friday announced a 4 percent increase in fees for the 2026 Hong Kong Diploma of Secondary Education (HKDSE) exams and the introduction of a new fees structure for private candidates. According to the Hong Kong Examinations and Assessment Authority (HKEAA), the fees for school candidates for key language and other subjects have been raised by HK$30 and HK$20 each respectively. For a candidate taking six subjects – two language and four other subjects – the total fees will amount to HK3,630. The HKEAA stated that the hike is similar to previous years and remains at a relatively moderate level, with the adjustment taking into account various factors. For private candidates, a flat fee of HK$595 will be charged and there will be a new two-tier fees structure depending on their residency status. Candidates who are non-Hong Kong permanent residents are required to pay HK$1,377 for each language subject and HK$1,119 for each additional subject, HK$600 more when compared with that for local residents. For non-permanent residents who are under 18 years old and sitting the exam for the first time, there will be a new special entry fee of HK$2,000 per person. That would mean examination fees of more than HK$9,800 for those taking four core subjects and two electives. The HKEAA said the fees and charges had been revised to optimise the use of resources and maintain the long-term financial stability of the body. "There has been a notable increase in the number of private candidates in recent years. Some of these candidates, holding non-HKDSE qualifications, are required to submit Special Entry applications, which necessitate substantial manpower and resources from the authority to carefully vet each case," it said. "Additional examination centres and personnel have also been arranged to accommodate the growing number of private candidates, further increasing the operational costs of the HKDSE."
South China Morning Post
2 days ago
- South China Morning Post
Pfizer, Chinese biotech firm 3SBio complete worldwide licensing deal for cancer drug
First announced in May, the deal will see 3SBio – based in Shenyang, capital of northeastern Liaoning province – receive a US$1.25 billion upfront payment from Pfizer for the exclusive right to sell its cancer drug, SSGJ-707, outside China. Under the terms of their agreement, Pfizer will also pay 3SBio up to US$150 million to solely develop and commercialise SSGJ-707 within the mainland, the two companies said on Thursday. Pfizer also agreed to buy 31.1 million new shares in S3Bio, or a 1.3 per cent equity stake, for HK$785 million, according to a stock exchange filing. The deal at HK$25.2055 per share represents a 17 per cent discount to its market price on Thursday. 3SBio's shares fell 6.41 per cent to HK$28.45 on Friday. The transaction reflected the strong momentum of Chinese biotech firms in the field of drugs research and the increased interest from major foreign pharmaceutical companies to license their intellectual property.
South China Morning Post
2 days ago
- South China Morning Post
Hong Kong life insurance sales jump 43% to record high in first quarter
Life insurance sales in Hong Kong rose 43 per cent in the first quarter to a record high on demand for protection and estate planning from high-net-worth customers and visitors from mainland China, as the city seeks to become a wealth management hub to rival global leaders like Switzerland. The industry wrote HK$93.4 billion (US$12 billion) worth of new life policies in the first quarter, up from HK$65.3 billion a year earlier, the Insurance Authority said on Friday. It was the highest first-quarter sales tally since the authority was established in 2016. Hong Kong had a record year in 2024, when insurers posted a 21.4 per cent jump in sales to HK$219.8 billion, courtesy of a world-record policy sold by HSBC Life. 'Hong Kong's insurance industry continued its strong momentum in early 2025, supported by sustained demand for savings, health, and protection products from both local customers and mainland Chinese visitors,' said Patrick Graham, CEO of Manulife Hong Kong and Macau. The regulator did not disclose policy sales to mainland visitors, having earlier decided to release such statistics after a review about the disclosures of non-local buyers.
